Healthcare DIVE March 27, 2024
Gross Medicare spending on the pricey drugs rose from $57 million in 2018 to $5.7 billion in 2022, according to a new analysis from the health policy group.
Medicare spending on pricey GLP-1 drugs like Ozempic has skyrocketed in recent years, and expanding the insurance program’s coverage of the drugs — like for weight loss — could cause spending to accelerate even more drastically, according to a new report.
Gross Medicare spending on GLP-1s rose from $57 million in 2018 to $5.7 billion in 2022, according to a KFF analysis of recent government data. As of 2022, Medicare covered three GLP-1s for diabetes: Ozempic and Rybelsus, manufactured by drugmaker Novo Nordisk, and Mounjaro, manufactured by drugmaker Eli Lilly.
“The fact...
Today's Sponsors
Today's Sponsor